Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Lung Neoplasms 22Carcinoma, Non-Small-Cell Lung 15Ovarian Neoplasms 12Fallopian Tube Neoplasms 11Carcinoma, Hepatocellular 9Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Mycosis Fungoides 5Leukemia, Lymphocytic, Chronic, B-Cell 5Carcinoma, Renal Cell 5Squamous Cell Carcinoma of Head and Neck 4Neoplasm Metastasis 4Lymphoma, T-Cell, Cutaneous 4Glioblastoma 4Colonic Neoplasms 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Sezary Syndrome 3Rectal Neoplasms 3Nasopharyngeal Carcinoma 3Multiple Myeloma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Lymphoma, B-Cell 3Endometrial Neoplasms 3Cholangiocarcinoma 3

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Disulfides × 1 year × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡